Health In Tech, Inc. (HIT) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
HIT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Health In Tech, Inc. (HIT) trades at a price-to-earnings ratio of 78.5x, with a stock price of $1.57 and trailing twelve-month earnings per share of $0.02.
The current P/E is 44% below its 5-year average of 140.2x. Over the past five years, HIT's P/E has ranged from a low of 33.6x to a high of 428.8x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Technology sector median P/E of 27.7x, HIT trades at a 184% premium to its sector peers. The sector includes 359 companies with P/E ratios ranging from 0.0x to 184.2x.
Relative to the broader market, HIT commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HIT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HIT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 50.3 | -Best | -4% | |
| $973M | 33.3 | -Best | +104%Best | |
| $336B | 27.9Lowest | -Best | -15% | |
| $111B | 62.8 | -Best | -62% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
HIT Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $1.59 | $0.02 | 79.5x | -43% |
| FY2025 Q3 | $3.21 | $0.03 | 121.6x | -13% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $0.88 | $0.02 | 37.6x | -73% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $0.66 | $0.02 | 33.6x | -76% |
| FY2024 Q4 | $5.36 | $0.01 | 428.8x | +206% |
Average P/E for displayed period: 140.2x
See HIT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HIT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HIT vs NVDA
Side-by-side business, growth, and profitability comparison vs NVIDIA Corporation.
Start ComparisonHIT — Frequently Asked Questions
Quick answers to the most common questions about buying HIT stock.
Is HIT stock overvalued or undervalued?
HIT trades at 78.5x P/E, below its 5-year average of 140.2x. At the 40th percentile of historical range, the stock is priced at a discount to its own history.
How does HIT's valuation compare to peers?
Health In Tech, Inc. P/E of 78.5x compares to sector median of 27.7x. The premium reflects expected growth above peers.
What is HIT's PEG ratio?
HIT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.